Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...

Bolt Biotherapeutics, Inc. (BOLT) has disclosed a new risk, in the Corporate Activity and Growth category. The restructuring initiative ...

SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...

Detailed price information for Sonnet Biot Inc (SONN-Q) from The Globe and Mail including charting and trades.

Sonnet BioTherapeutics Holdings, Inc. disclosed in an 8-K filing with the SEC on November 6, 2024, that it has successfully completed an underwritten public offering aimed at raising $5.0 million in ...

Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a <a target ...

Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. The stock gained 60% to ...

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer ...

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have ...

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company ...